Planning & Evaluation

规划

基本信息

批准号：
10762293
负责人：
Kendrick Davis
金额：
$ 11.11万
依托单位：
UNIVERSITY OF CALIFORNIA RIVERSIDE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10762293
关键词：
Award California City of Hope Comprehensive Cancer Center Clinical Trials Collaborations Communities Comprehensive Cancer Center Contractor Databases Education Educational process of instructing Educational workshop Effectiveness Equity Evaluation Feedback Funding Future Goals Grant Individual Joints Knowledge Leadership Measures Mentors Mentorship Modeling Monitor Outcome Measure Performance Pilot Projects Play Process Program Evaluation Progress Reports Publications Recommendation Reporting Research Research Personnel Resources Structure Surveys Therapeutic Training Training Programs Training and Education Translational Research United States National Institutes of Health Universities Work anticancer research cancer health disparity career career development drug development equity, diversity, and inclusion health disparity improved insight meetings outreach programs success webinar

项目摘要

The goals of the Planning and Evaluation Core (PEC) are to monitor, evaluate, and assess the progress of our U54 Partnerships in meeting its milestones, objectives, and goals. The Core supports our University of California, Riverside (UCR) – City of Hope Comprehensive Cancer Center (CoHCCC) U54 Partnership’s goals of capacity- building, education, and training. Together in this U54, UCR and CoHCCC aim to develop the collaborations, translational resources, and training programs to enhance diversity in cancer research and achieve equity in drug development - throughout the entire drug development pipeline. To achieve our PEC’s goals we are guided by four boards – the Internal Advisory Board (IAB), External Advisory Board (EAB), Community Advisory Board (CAB), and Diversity, Equity, and Inclusion Board (DEI). Our IAB and EAB have served a key role in guiding our P20 planning grant; in our proposed U54 these two boards will be joined by our newly created CAB and DEI. The inclusion of these two new boards underscores our U54’s commitment to 1) serving the diverse individuals that live in our Southern California communities and 2) to mentor and train a diverse early-stage investigators who are committed to eliminating our current disparities in cancer therapeutics, drug development, and access to clinical trials. Through the activities and oversight of the PEC, our four advisory boards will 1) conduct evaluation, tracking, and reporting of the progress of projects and cores and 2) provide focused feedback to program U54 leadership and investigators. As in our P20 planning grant, the U54 PEC will work with the IAB to provide a structured and rigorous review process to select new Full and Pilot projects as well as Mini-Pilots for the Capacity Core. The PEC will assess all components of our U54 partnership. The PEC will assure that the 1) Research and Evaluation Core training and education programs are effective in providing education and building capacity, 2) Outreach Core works with investigators to be inclusive of the communities we serve, and 3) Capacity Core identifies provides early-stage investigators (ESI) with mentorship in target identification, drug development, and clinical trials. We anticipate that together our Cores will play a key role in developing future U54 projects that build UCR’s capacity in drug development and clinical trials.

计划和评估核心（PEC）的目标是监视，评估和评估我们的进度 U54伙伴关系实现其里程碑，目标和目标。核心支持我们的加利福尼亚大学 Riverside（UCR） - 希望之城综合癌症中心（COHCCC）U54伙伴关系的目标目标 - 建筑，教育和培训。在此U54中，UCR和CoHCCC旨在开发合作，转化资源和培训计划，以增强癌症研究的多样性并获得公平性药物开发 - 在整个药物开发管道中。为了实现我们的PEC目标，我们得到了指导由四个董事会 - 内部顾问委员会（IAB），外部咨询委员会（EAB），社区咨询委员会（CAB）以及多样性，公平和包容委员会（DEI）。我们的IAB和EAB在指导我们的 P20计划赠款；在我们提出的U54中，这两个板将由我们新创建的出租车和Dei加入。包括这两个新董事会的内容强调了我们U54对1）为潜水员服务的承诺居住在我们南加州的社区，2）心理和培训潜水员的早期调查员致力于消除我们目前在癌症治疗，药物开发和进入方面的差异进行临床试验。通过PEC的活动和监督，我们的四个咨询委员会将进行1）评估，跟踪和报告项目和核心的进度以及2）为重点反馈提供计划U54领导力和调查人员。与我们的P20计划赠款一样，U54 PEC将与IAB合作提供一个结构化和严格的审核过程，以选择新的完整和试点项目以及迷你行李容量核心。 PEC将评估我们U54合作伙伴关系的所有组件。 PEC将确保 1）研究和评估核心培训和教育计划有效地提供教育和建筑能力，2）与调查人员合作的外展核心包括我们所服务的社区，3）能力核心通过目标识别，药物的指导识别早期研究者（ESI）开发和临床试验。我们预计我们的核心将在发展未来中发挥关键作用 U54项目在药物开发和临床试验中的能力增强。